These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31806587)

  • 21. The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris.
    Nakao M; Asano Y; Nakamura K; Shida R; Takahashi T; Yoshizaki A; Mitsui A; Shibata S; Araki M; Watanabe R; Ikawa Y; Toyoda C; Oka H; Sato S
    Eur J Dermatol; 2016 Aug; 26(4):404-5. PubMed ID: 27086491
    [No Abstract]   [Full Text] [Related]  

  • 22. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study.
    Bae JM; Lee HH; Lee BI; Lee KM; Eun SH; Cho ML; Kim JS; Park JM; Cho YS; Lee IS; Kim SW; Choi H; Choi MG
    Aliment Pharmacol Ther; 2018 Jul; 48(2):196-205. PubMed ID: 29869804
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palmoplantar pustulosis by adalimumab in a patient with Crohn disease.
    Ortiz Salvador JM; Cubells Sánchez L; Subiabre Ferrer D
    Med Clin (Barc); 2016 Dec; 147(12):565. PubMed ID: 27431884
    [No Abstract]   [Full Text] [Related]  

  • 24. Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study.
    Paul C; van de Kerkhof P; Puig L; Unnebrink K; Goldblum O; Thaçi D
    Eur J Dermatol; 2012; 22(6):762-9. PubMed ID: 23178916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic.
    Adenubiova E; Arenberger P; Gkalpakioti P; Arenbergerova M; Jircikova J; Dolezal T; Gkalpakiotis S
    J Dermatolog Treat; 2018 Sep; 29(6):579-582. PubMed ID: 29307245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune thrombocytopenic purpura associated with inactive ulcerative colitis in chronic treatment with adalimumab.
    Velayos Jiménez B; Cuello García R; Del Olmo Martínez L; Macho Conesa A; Fernández Salazar L
    Gastroenterol Hepatol; 2020 Jan; 43(1):28-29. PubMed ID: 31488320
    [No Abstract]   [Full Text] [Related]  

  • 27. Paradoxical case effects of psoriasis following adalimumab therapy: A case series.
    Zangrilli A; Bavetta M; Mazzilli S; Garofalo V; Bianchi L
    Dermatol Ther; 2018 Nov; 31(6):e12729. PubMed ID: 30239070
    [No Abstract]   [Full Text] [Related]  

  • 28. Retention Rate, Persistence and Safety of Adalimumab in Inflammatory Bowel Disease: A Real-Life, 9-Year, Single-Center Experience in Italy.
    Sartini A; Scaioli E; Liverani E; Bellanova M; Ricciardiello L; Bazzoli F; Belluzzi A
    Dig Dis Sci; 2019 Mar; 64(3):863-874. PubMed ID: 30334112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.
    Whitlock SM; Enos CW; Armstrong AW; Gottlieb A; Langley RG; Lebwohl M; Merola JF; Ryan C; Siegel MP; Weinberg JM; Wu JJ; Van Voorhees AS
    J Am Acad Dermatol; 2018 Feb; 78(2):383-394. PubMed ID: 29332708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adalimumab-induced erythrodermic reactions.
    Nowsheen S; Kohorst JJ; El-Azhary RA
    Int J Dermatol; 2019 Oct; 58(10):e204-e206. PubMed ID: 31135963
    [No Abstract]   [Full Text] [Related]  

  • 31. Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis.
    Andrisani G; Gremese E; Guidi L; Papa A; Marzo M; Felice C; Pugliese D; Armuzzi A
    Reumatismo; 2013 May; 65(2):75-8. PubMed ID: 23877411
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adalimumab-induced apoptotic enteropathy.
    Parikh J; Kerman DH; Garcia-Buitrago MT
    Colorectal Dis; 2016 Apr; 18(4):419-21. PubMed ID: 26799728
    [No Abstract]   [Full Text] [Related]  

  • 33. The economics of adalimumab for ulcerative colitis.
    Xie F
    Expert Rev Pharmacoecon Outcomes Res; 2015 Jun; 15(3):373-7. PubMed ID: 25817776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab use in patients with psoriasis and hepatitis B: a case series.
    No DJ; Amin M; Wu JJ
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e548-e550. PubMed ID: 28622425
    [No Abstract]   [Full Text] [Related]  

  • 35. Interactions Between Thiopurine Metabolites, Adalimumab, and Antibodies Against Adalimumab in Previously Infliximab-Treated Patients with Inflammatory Bowel Disease.
    Holmstrøm RB; Mogensen DV; Brynskov J; Ainsworth MA; Nersting J; Schmiegelow K; Steenholdt C
    Dig Dis Sci; 2018 Jun; 63(6):1583-1591. PubMed ID: 29564674
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
    Rutka M; Bálint A; Farkas K; Palatka K; Lakner L; Miheller P; Rácz I; Hegede G; Vincze Á; Horváth G; Szabó A; Nagy F; Szepes Z; Gábor Z; Zsigmond F; Zsóri Á; Juhász M; Csontos Á; Szűcs M; Bor R; Milassin Á; Molnár T
    Orv Hetil; 2016 May; 157(18):706-11. PubMed ID: 27106726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ADALIMUMAB FOR ULCERATIVE COLITIS: RESULTS OF A BRAZILIAN MULTICENTER OBSERVATIONAL STUDY.
    Zacharias P; Damião AOMC; Moraes AC; Teixeira FV; Ludvig JC; Nones RB; Saad-Hossne R; Sassaki LY; Silva RPLD; Facchin L; Olandoski M; Kotze PG
    Arq Gastroenterol; 2017 Dec; 54(4):321-327. PubMed ID: 28977114
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of psoriasis with adalimumab.
    Pitarch G; Sanchez-Carazo JL; Mahiques L; Perez-Ferriols MA; Fortea JM
    Clin Exp Dermatol; 2007 Jan; 32(1):18-22. PubMed ID: 17305904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adalimumab in ulcerative colitis: ready for prime time.
    Danese S
    Dig Liver Dis; 2013 Jan; 45(1):8-13. PubMed ID: 22766323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis.
    Baki E; Zwickel P; Zawierucha A; Ehehalt R; Gotthardt D; Stremmel W; Gauss A
    World J Gastroenterol; 2015 Mar; 21(11):3282-90. PubMed ID: 25805935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.